LOGIN  |  REGISTER
Surmodics
Astria Therapeutics

Stryker declares a $0.80 per share quarterly dividend

December 05, 2023 | Last Trade: US$358.92 0.92 0.26

Kalamazoo, Michigan, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable January 31, 2024 to shareholders of record at the close of business on December 29, 2023, representing an increase of 6.7% versus the prior year and previous quarter.

 “We continue to deliver strong growth and solid financial performance, and aligning with our capital allocation strategy we are raising our dividend 6.7%,” said Kevin Lobo, Chair and Chief Executive Officer.

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB